
HIV / AIDS
Latest News
Latest Videos

More News

People who inject drugs (PWID) are at a higher risk for hepatitis C and HIV. A new study examined point of care initiatives and how to better support this population with intervention efforts.

This week a new vaccine for HIV is under development, a COVID-19 vaccine receives WHO emergency approval, and several local US health departments receive funding to combat antimicrobial resistance.

A new study warns an increase in costs could lead to new infections.

Infants with HIV could be spared from requiring lifetime ART if treated within hours of birth to disrupt formation of HIV viral reservoirs.

Therapy development, management improvements, and public health initiatives have all helped to change the trajectory of health outcomes for many, but still millions of people remain behind and are not in the continuum of care.

Salem Hospital faces a class action lawsuit over potential hepatitis and HIV exposure to hundreds of patients. The lawsuit alleges negligence and emotional distress, with the hospital claiming a minimal infection risk.

Learning about these barriers is the first step to overcoming them.

Emergency departments (EDs) are an important entry point into the health care system and have been identified as a location with opportunity for increased HIV diagnosis and management.

The antiretroviral, lenacapavir (Sunlenca 463.5 mg/1.5 mL injection), had reported resistance in only a minority of study participants according to the latest findings released at a conference.

This action paves the way for this long-acting injectable to be used in several countries on the European continent.

Barriers to Health Care Transition in Adolescents and Young Adults With Early Acquired HIV Infection
Unique challenges can affect the success of the shift from pediatric to adult care settings.


The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.

The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.

The twice-yearly injectable shown to be beneficial in conjunction with an optimized background regimen.

A new study being presented at the ongoing IAS conference showed that people with HIV found the injectable therapy, Cabotegravir plus long-acting Rilpivirine (Cabenuva) is more conducive to today’s lifestyles, reduced stigma, and improved adherence.

A new study shows the use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events. The data is being reported at the International AIDS Society Conference.

New study demonstrates benefit of adhering to treatment regimen and also calls for simplifying viral testing in other parts of the world where updated panels technology may not be available.

A congressional subcommittee aims at reducing HIV-related budget items by over half a billion dollars.

New data from AIDSVu show significant disparities in the usage of HIV pre-exposure prophylaxis (PrEP). Black and Hispanic/Latinx Americans are underrepresented among PrEP users, despite accounting for a significant portion of new HIV diagnoses.

HIV testing is for everyone, explains Dr. Uri Belkind, regardless of sexual orientation, race, or gender.

As this annual day of recognition gets underway, free testing can be found throughout the United States.

This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.

Among mpox patients treated with tecovirimat, there was no difference in treatment outcomes between those living with HIV and those without HIV.

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.

























































































































































